MapLight Announces Topline Results From Phase 2 IRIS Study for ML-004
MapLight Announces Topline Results From Phase 2 IRIS Study for ML-004.
MapLight Therapeutics
Clinical-stage neuroscience company developing small-molecule therapies for autism spectrum disorder, schizophrenia, and other CNS conditions.
Company Info
Sector:Small Molecule Pharma
Headquarters:South San Francisco, California, USA
Founded:2018
Website:maplightrx.com/
Upcoming Milestones & Key Dates
2026 Q3
Regulatory interaction
FDA meeting on ML-004 in autism
2026 H2
Clinical readout
Phase 2 data readout for ML-004
Clinical Development Pipeline
ML-004
Target: M1/M4 muscarinic agonistML-007
Target: M1/M4 muscarinic agonistML-009
Target: D2/5-HT2A antagonistRecent News
Leadership Team
Christopher Kroeger, M.D.
Chief Executive Officer
Careers & Job Openings